Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes

被引:105
作者
Runge, D [1 ]
Köhler, C
Kostrubsky, VE
Jäger, D
Lehmann, T
Runge, DM
May, U
Stolz, DB
Strom, SC
Fleig, WE
Michalopoulos, GK
机构
[1] Univ Halle Wittenberg, Innere Med Klin 1, D-06097 Halle, Germany
[2] Univ Halle Wittenberg, Inst Umwelttoxikol, D-06097 Halle, Germany
[3] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15261 USA
关键词
human hepatocytes; antibiotics; barbiturates; aromatic hydrocarbons; cytochrome P450; P-glycoprotein; multidrug-resistance-associated protein;
D O I
10.1006/bbrc.2000.2902
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human hepatocytes cultured serum-free for up to 6 weeks were used to study expression and induction of enzymes and membrane transport proteins involved in drug metabolism. Phase I drug metabolizing enzymes cytochrome P450 (CYP)1A1, CYP1A2, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 were detected by Western blot analyses and, when appropriate, by enzymatic assays for ethoxyresorufin-O-deethylase(EROD)-activity and testosterone-6 beta-hydroxylase(T6H)-activity. Expression of the membrane transporter multi-drug resistance protein (P-glycoprotein, MDR-1), multidrug resistance-associated protein (MRP-1), and lung-resistance protein (LRP) was maintained during the culture as detected by RT-PCR, and Western blot analyses. Model inducers like rifampicin, phenobarbital, or 3-methylcholanthrene and beta-napthoflavone were able to induce CYP1A or CYP3A4 as well as EROD or T6H activities for up to 30 days. CYP2C9, CYP2C19 and CYP2E1 expression was maintained but not inducible for 48 days. Also, rifampicin and phenobarbital were unable to increase MDR-1 and MRP-1 protein levels significantly. (C) 2000 Academic Press.
引用
收藏
页码:333 / 341
页数:9
相关论文
共 47 条
[1]   LIDOCAINE METABOLISM IN HUMAN-LIVER MICROSOMES BY CYTOCHROME-P450IIIA4 [J].
BARGETZI, MJ ;
AOYAMA, T ;
GONZALEZ, FJ ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) :521-527
[2]   A 190-KILODALTON PROTEIN OVEREXPRESSED IN NON-P-GLYCOPROTEIN-CONTAINING MULTIDRUG-RESISTANT CELLS AND ITS RELATIONSHIP TO THE MRP GENE [J].
BARRAND, MA ;
HEPPELLPARTON, AC ;
WRIGHT, KA ;
RABBITTS, PH ;
TWENTYMAN, PR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (02) :110-117
[3]   CATALYTIC ACTIVITIES OF HUMAN LIVER CYTOCHROME-P-450-IIIA4 EXPRESSED IN SACCHAROMYCES-CEREVISIAE [J].
BRIAN, WR ;
SARI, MA ;
IWASAKI, M ;
SHIMADA, T ;
KAMINSKY, LS ;
GUENGERICH, FP .
BIOCHEMISTRY, 1990, 29 (51) :11280-11292
[4]  
Chang TKH, 1997, CANCER RES, V57, P1946
[5]   DIFFERENTIAL MODULATION OF P-GLYCOPROTEIN EXPRESSION BY DEXAMETHASONE AND 3-METHYCHOLANTHRENE IN RAT HEPATOCYTE PRIMARY CULTURES [J].
CHIELI, E ;
SANTONIRUGIU, E ;
CERVELLI, F ;
SABBATINI, A ;
PETRINI, M ;
ROMITI, N ;
PAOLICCHI, A ;
TONGIANI, R .
CARCINOGENESIS, 1994, 15 (02) :335-341
[6]   EXPRESSION OF THE MULTIDRUG RESISTANCE GENE-PRODUCT (P-GLYCOPROTEIN) IN HUMAN NORMAL AND TUMOR-TISSUES [J].
CORDONCARDO, C ;
OBRIEN, JP ;
BOCCIA, J ;
CASALS, D ;
BERTINO, JR ;
MELAMED, MR .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1990, 38 (09) :1277-1287
[7]  
Donato MT, 1998, J PHARMACOL EXP THER, V284, P760
[8]   A MICROASSAY FOR MEASURING CYTOCHROME-P450IA1 AND CYTOCHROME-P450IIB1 ACTIVITIES IN INTACT HUMAN AND RAT HEPATOCYTES CULTURED ON 96-WELL PLATES [J].
DONATO, MT ;
GOMEZLECHON, MJ ;
CASTELL, JV .
ANALYTICAL BIOCHEMISTRY, 1993, 213 (01) :29-33
[9]   Long-term primary cultures of adult human hepatocytes [J].
Ferrini, JB ;
Pichard, L ;
Domergue, J ;
Maurel, P .
CHEMICO-BIOLOGICAL INTERACTIONS, 1997, 107 (1-2) :31-45
[10]   REGULATION OF 2-ACETYLAMINOFLUORENE MEDIATED AND 3-METHYLCHOLANTHRENE MEDIATED INDUCTION OF MULTIDRUG RESISTANCE AND CYTOCHROME-P450IA GENE FAMILY EXPRESSION IN PRIMARY HEPATOCYTE CULTURES AND RAT-LIVER [J].
GANT, TW ;
SILVERMAN, JA ;
BISGAARD, HC ;
BURT, RK ;
MARINO, PA ;
THORGEIRSSON, SS .
MOLECULAR CARCINOGENESIS, 1991, 4 (06) :499-509